Article List
List all articles in the database by earliest discovery_date
GET /articles/?format=api&page=2430
{ "count": 24858, "next": "http://api.gregory-ms.com/articles/?format=api&page=2431", "previous": "http://api.gregory-ms.com/articles/?format=api&page=2429", "results": [ { "article_id": 580, "title": "MSProDiscuss - Development of a digital anamnesis tool to identify disease progression in multiple sclerosis", "summary": "<div><p>Fortschr Neurol Psychiatr. 2021 Mar 15. doi: 10.1055/a-1397-6851. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">During the course of Multiple Sclerosis (MS), most patients with relapsing remitting MS (RRMS) convert to secondary progressive MS (SPMS), an MS-phenotype associated with a steady deterioration of functional ability independent from relapses and worsened prognosis. Due to the heterogeneity of this conversion, SPMS-diagnosis is often challenging and made retrospectively with a delay of several years. In this review, we first discuss advantages and limitations of screening tools for early SPMS-detection such as the <i>SPMS nomogram</i>, the <i>MS prediction score</i>, and the <i>best SPMS definition</i> approach. These screening tools might help to shorten the phase of diagnostic uncertainty. We then focus on the development of <i>MSProDiscuss</i>, a novel web-based tool that helps the treating neurologist to systematically assesses parameters highly relevant for SPMS-conversion during routine anamnesis. These parameters involve disease activity, symptoms, and impacts of the patient's overall symptoms. In a recent validation study, <i>MSProDiscuss</i> demonstrated high sensitivity, specificity, and interrater reliability. <i>MSProDiscuss</i> does not impose an additional time burden on the treating neurologist and its results are easy to interpret by a simple traffic light system. In first usability tests, it was therefore assessed as a helpful tool for the clinical routine. The early detection of clinically significant progression by diagnostic tools such as <i>MSProDiscuss</i> could open a time-window for therapeutic interventions.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33723837/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210316142551&v=2.14.3\">33723837</a> | DOI:<a href=\"https://doi.org/10.1055/a-1397-6851\">10.1055/a-1397-6851</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33723837/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-07T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Georg Thieme Verlag KG", "container_title": "Fortschritte der Neurologie · Psychiatrie", "authors": [ { "author_id": 185213, "given_name": "Hernan", "family_name": "Inojosa", "ORCID": "http://orcid.org/0000-0002-1377-836X", "country": "DE" }, { "author_id": 184946, "given_name": "Katja", "family_name": "Akgün", "ORCID": "http://orcid.org/0000-0003-1371-5032", "country": null }, { "author_id": 244773, "given_name": "Katrin", "family_name": "Haacke", "ORCID": null, "country": null }, { "author_id": 153754, "given_name": "Tjalf", "family_name": "Ziemssen", "ORCID": "http://orcid.org/0000-0001-8799-8202", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-16T18:25:53Z", "noun_phrases": [ "MSProDiscuss - Development", "a digital anamnesis tool", "disease progression", "multiple sclerosis" ], "doi": "10.1055/a-1397-6851", "access": "restricted", "takeaways": " MSProDiscuss is a web-based tool that helps the treating neurologist to systematically assesses parameters highly relevant for SPMS-conversion during routine anamnesis . Early detection of clinically significant progression by diagnostic tools could open a time-window for therapeutic interventions .", "categories": [] }, { "article_id": 578, "title": "Efficacy of fingolimod after switching from interferon beta-1a in an adolescent with multiple sclerosis: case report", "summary": "<div><p>Neurol Sci. 2021 Mar 16. doi: 10.1007/s10072-021-05170-w. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">Pediatric-onset multiple sclerosis (POMS) accounts for approximately 2-10% of all cases of multiple sclerosis (MS) and is associated with higher levels of disease activity than adult-onset MS, including higher rates of clinical relapse and a greater incidence of new T2 lesions on magnetic resonance imaging (MRI). First-line therapy for POMS usually includes interferon β or glatiramer acetate; however, there is limited evidence from randomized trials regarding the safety and efficacy of these disease-modifying drugs in pediatric patients. Fingolimod represents a second-line therapy option for relapsing-remitting MS in pediatric patients. Here, we report the case of a 14-year-old girl with a diagnosis of POMS who started interferon β-1a as first-line therapy and then switched to fingolimod after 12 months due to radiologic progression and clinical relapse. The patient subsequently experienced clinical stability and showed minimal radiologic activity on follow-up MRI. Our case demonstrates the real-world clinical effectiveness and safety of fingolimod in pediatric MS and is in line with the results of previous randomized and observational studies.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33723709/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210316142551&v=2.14.3\">33723709</a> | DOI:<a href=\"https://doi.org/10.1007/s10072-021-05170-w\">10.1007/s10072-021-05170-w</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33723709/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-05T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "Neurological Sciences", "authors": [ { "author_id": 182610, "given_name": "Annalisa", "family_name": "Amidei", "ORCID": "http://orcid.org/0000-0003-4833-6948", "country": null }, { "author_id": 154760, "given_name": "Gabriele", "family_name": "Siciliano", "ORCID": "http://orcid.org/0000-0002-6142-2384", "country": null }, { "author_id": 244571, "given_name": "Livia", "family_name": "Pasquali", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-16T18:25:53Z", "noun_phrases": [ "fingolimod", "interferon beta-1a", "an adolescent", "multiple sclerosis" ], "doi": "10.1007/s10072-021-05170-w", "access": "restricted", "takeaways": " Fingolimod represents a second-line therapy option for relapsing-remitting MS in pediatric patients . POMS accounts for approximately 2-10% of all cases of multiple sclerosis .", "categories": [ { "category_id": 1, "category_description": "Fingolimod, also known as Gilenya is a type of medicine known as a ‘disease-modifying therapy’ that is used to treat adults and children over 10 years of age with highly active relapsing-remitting multiple sclerosis (MS), a disease of the nerves in which inflammation destroys the protective sheath surrounding the nerve cells. ‘Relapsing-remitting’ means that the patient has flare-ups of symptoms (relapses) followed by periods of recovery (remissions). Gilenya is used when the disease remains active despite appropriate treatment with at least one other disease-modifying therapy, or is severe and getting worse rapidly.\r\n\r\nhttps://www.ema.europa.eu/en/medicines/human/EPAR/gilenya", "category_name": "Fingolimod", "category_slug": "fingolimod", "category_terms": [ "fingolimod", "gilenya" ], "article_count": 260 } ] }, { "article_id": 581, "title": "Time to walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials", "summary": "<div><p>Eur J Neurol. 2021 Mar 16. doi: 10.1111/ene.14823. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">BACKGROUND: Requiring a walking aid is a fundamental milestone in MS, represented by Expanded Disability Status Scale (EDSS) score ≥6.0. Here we assess the effect of ocrelizumab on time to EDSS≥6.0 in relapsing MS.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: Time to EDSS≥6.0 confirmed for ≥24 and ≥48 weeks was assessed over 6.5 years (336 weeks) in the double-blind and open-label extension periods of OPERA I (NCT01247324) and OPERA II (NCT01412333).</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: Time to reach EDSS≥6.0 was significantly delayed in those initially randomized to ocrelizumab versus interferon. Over 6.5 years, the risk of requiring a walking aid confirmed for ≥24 weeks was 34% lower among those who initiated ocrelizumab earlier vs. delayed treatment (average HR DBP+OLE [95%CI]: 0.66 [0.45-0.95]; P = 0.024); the risk of requiring a walking aid confirmed for ≥48 weeks was 46% lower (average HR DBP+OLE [95%CI]: 0.54 [0.35-0.83]; P = 0.004).</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSION: The reduced risk of requiring a walking aid in earlier initiators of ocrelizumab demonstrates the long-term implications of earlier highly effective treatment.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33724637/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210316142551&v=2.14.3\">33724637</a> | DOI:<a href=\"https://doi.org/10.1111/ene.14823\">10.1111/ene.14823</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33724637/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-12-19T00:30:38.720000Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Wiley", "container_title": "European Journal of Neurology", "authors": [ { "author_id": 143429, "given_name": "Gavin", "family_name": "Giovannoni", "ORCID": "http://orcid.org/0000-0001-9995-1700", "country": null }, { "author_id": 147953, "given_name": "Ludwig", "family_name": "Kappos", "ORCID": "http://orcid.org/0000-0003-4175-5509", "country": null }, { "author_id": 229913, "given_name": "Jerome", "family_name": "de Seze", "ORCID": "http://orcid.org/0000-0002-7197-7578", "country": null }, { "author_id": 155520, "given_name": "Stephen L.", "family_name": "Hauser", "ORCID": "http://orcid.org/0000-0002-4932-4001", "country": null }, { "author_id": 189658, "given_name": "James", "family_name": "Overell", "ORCID": "http://orcid.org/0000-0002-3998-9819", "country": null }, { "author_id": 270855, "given_name": "Harold", "family_name": "Koendgen", "ORCID": null, "country": null }, { "author_id": 268216, "given_name": "Marianna", "family_name": "Manfrini", "ORCID": null, "country": null }, { "author_id": 324594, "given_name": "Qing", "family_name": "Wang", "ORCID": "http://orcid.org/0000-0003-1284-4705", "country": null }, { "author_id": 151533, "given_name": "Jerry S.", "family_name": "Wolinsky", "ORCID": "http://orcid.org/0000-0002-8197-2762", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-16T18:25:53Z", "noun_phrases": [ "aid", "6.5 years", "ocrelizumab treatment", "patients", "multiple sclerosis", "the OPERA" ], "doi": "10.1111/ene.14823", "access": "open", "takeaways": " Requiring a walking aid is a fundamental milestone in MS . Time to reach EDSS≥6.0 was significantly delayed in those initially randomized to ocrelizumab versus interferon .", "categories": [ { "category_id": 8, "category_description": "", "category_name": "Ocrelizumab", "category_slug": "ocrelizumab", "category_terms": [ "ocrelizumab", "ocrevus" ], "article_count": 234 } ] }, { "article_id": 579, "title": "Imaging meningeal inflammation in CNS autoimmunity identifies a therapeutic role for BTK inhibition", "summary": "<div><p>Brain. 2021 Mar 16:awab045. doi: 10.1093/brain/awab045. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">Leptomeningeal inflammation in multiple sclerosis is associated with worse clinical outcomes and greater cortical pathology. Despite progress in identifying this process in multiple sclerosis patients using post-contrast fluid-attenuated inversion recovery imaging, early trials attempting to target meningeal inflammation have been unsuccessful. There is a lack of appropriate model systems to screen potential therapeutic agents targeting meningeal inflammation. We utilized ultra-high field (11.7 T) MRI to perform post-contrast imaging in SJL/J mice with experimental autoimmune encephalomyelitis induced via immunization with proteolipid protein peptide (PLP139-151) and complete Freund's adjuvant. Imaging was performed in both a cross-sectional and longitudinal fashion at time points ranging from 2 to 14 weeks post-immunization. Following imaging, we euthanized animals and collected tissue for pathological evaluation, which revealed dense cellular infiltrates corresponding to areas of contrast enhancement involving the leptomeninges. These areas of meningeal inflammation contained B cells (B220+), T cells (CD3+) and myeloid cells (Mac2+). We also noted features consistent with tertiary lymphoid tissue within these areas, namely the presence of peripheral node addressin-positive structures, C-X-C motif chemokine ligand-13 (CXCL13)-producing cells and FDC-M1+ follicular dendritic cells. In the cortex adjacent to areas of meningeal inflammation we identified astrocytosis, microgliosis, demyelination and evidence of axonal stress/damage. Since areas of meningeal contrast enhancement persisted over several weeks in longitudinal experiments, we utilized this model to test the effects of a therapeutic intervention on established meningeal inflammation. We randomized mice with evidence of meningeal contrast enhancement on MRI scans performed at 6 weeks post-immunization, to treatment with either vehicle or evobrutinib [a Bruton tyrosine kinase (BTK) inhibitor] for a period of 4 weeks. These mice underwent serial imaging; we examined the effect of treatment on the areas of meningeal contrast enhancement and noted a significant reduction in the evobrutinib group compared to vehicle (30% reduction versus 5% increase; P = 0.003). We used ultra-high field MRI to identify areas of meningeal inflammation and to track them over time in SJL/J mice with experimental autoimmune encephalomyelitis, and then used this model to identify BTK inhibition as a novel therapeutic approach to target meningeal inflammation. The results of this study provide support for future studies in multiple sclerosis patients with imaging evidence of meningeal inflammation.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33724342/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210316142551&v=2.14.3\">33724342</a> | DOI:<a href=\"https://doi.org/10.1093/brain/awab045\">10.1093/brain/awab045</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33724342/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-06-21T23:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Oxford University Press (OUP)", "container_title": "Brain", "authors": [ { "author_id": 149197, "given_name": "Pavan", "family_name": "Bhargava", "ORCID": "http://orcid.org/0000-0002-7947-9418", "country": null }, { "author_id": 204125, "given_name": "Sol", "family_name": "Kim", "ORCID": "http://orcid.org/0000-0002-5037-5068", "country": null }, { "author_id": 244761, "given_name": "Arthur A", "family_name": "Reyes", "ORCID": null, "country": null }, { "author_id": 244763, "given_name": "Roland", "family_name": "Grenningloh", "ORCID": null, "country": null }, { "author_id": 147734, "given_name": "Martina", "family_name": "Absinta", "ORCID": "http://orcid.org/0000-0003-0276-383X", "country": null }, { "author_id": 244767, "given_name": "Carlos", "family_name": "Pardo", "ORCID": null, "country": null }, { "author_id": 244768, "given_name": "Peter", "family_name": "Van Zijl", "ORCID": null, "country": null }, { "author_id": 244770, "given_name": "Jiangyang", "family_name": "Zhang", "ORCID": null, "country": null }, { "author_id": 244771, "given_name": "Peter A", "family_name": "Calabresi", "ORCID": null, "country": null }, { "author_id": 326609, "given_name": "Ursula", "family_name": "Boschert", "ORCID": "http://orcid.org/0000-0001-7541-5284", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-16T18:25:53Z", "noun_phrases": [ "Imaging meningeal inflammation", "CNS autoimmunity", "a therapeutic role", "BTK inhibition" ], "doi": "10.1093/brain/awab045", "access": "open", "takeaways": " Leptomeningeal inflammation in multiple sclerosis is associated with worse clinical outcomes and greater cortical pathology . We used ultra-high field MRI to identify areas of meningeal inflammation and to track them over time in SJL/J mice with experimental autoimmune encephalomyelitis . We then used this model to identify BTK inhibition as a novel therapeutic approach .", "categories": [] }, { "article_id": 568, "title": "Sulfasalazine modifies metabolic profiles and enhances cisplatin chemosensitivity on cholangiocarcinoma cells in in vitro and in vivo models", "summary": "Background: Sulfasalazine (SSZ) is widely known as an xCT inhibitor suppressing CD44v9-expressed cancer stem-like cells (CSCs) being related to redox regulation. Cholangiocarcinoma (CCA) has a high recurrence rate and no effective chemotherapy. A recent report revealed high levels of CD44v9-positive cells in CCA patients. Therefore, a combination of drugs could prove a suitable strategy for CCA treatment via individual metabolic profiling.MethodsWe examined the effect of xCT-targeted CD44v9-CSCs using sulfasalazine combined with cisplatin (CIS) or gemcitabine in CCA in vitro and in vivo models and did NMR-based metabolomics analysis of xenograft mice tumor tissues.ResultsOur findings suggest that combined SSZ and CIS leads to a higher inhibition of cell proliferation and induction of cell death than CIS alone in both in vitro and in vivo models. Xenograft mice showed that the CD44v9-CSC marker and CK-19-CCA proliferative marker were reduced in the combination treatment. Interestingly, different metabolic signatures and significant metabolites were observed in the drug-treated group compared with the control group that revealed the cancer suppression mechanisms.ConclusionsSSZ could improve CCA therapy by sensitization to CIS through killing CD44v9-positive cells and modifying the metabolic pathways, in particular tryptophan degradation (i.e., kynurenine pathway, serotonin pathway) and nucleic acid metabolism.", "link": "https://cancerandmetabolism.biomedcentral.com/articles/10.1186/s40170-021-00249-6", "published_date": "2021-03-16T00:00:00Z", "sources": [ "BioMedCentral" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "Cancer & Metabolism", "authors": [ { "author_id": 244672, "given_name": "Malinee", "family_name": "Thanee", "ORCID": null, "country": null }, { "author_id": 244675, "given_name": "Sureerat", "family_name": "Padthaisong", "ORCID": null, "country": null }, { "author_id": 244677, "given_name": "Manida", "family_name": "Suksawat", "ORCID": null, "country": null }, { "author_id": 244678, "given_name": "Hasaya", "family_name": "Dokduang", "ORCID": null, "country": null }, { "author_id": 244679, "given_name": "Jutarop", "family_name": "Phetcharaburanin", "ORCID": null, "country": null }, { "author_id": 244681, "given_name": "Poramate", "family_name": "Klanrit", "ORCID": null, "country": null }, { "author_id": 244683, "given_name": "Attapol", "family_name": "Titapun", "ORCID": null, "country": null }, { "author_id": 244684, "given_name": "Nisana", "family_name": "Namwat", "ORCID": null, "country": null }, { "author_id": 244685, "given_name": "Arporn", "family_name": "Wangwiwatsin", "ORCID": null, "country": null }, { "author_id": 244687, "given_name": "Prakasit", "family_name": "Sa-ngiamwibool", "ORCID": null, "country": null }, { "author_id": 244688, "given_name": "Narong", "family_name": "Khuntikeo", "ORCID": null, "country": null }, { "author_id": 244689, "given_name": "Hideyuki", "family_name": "Saya", "ORCID": null, "country": null }, { "author_id": 197827, "given_name": "Watcharin", "family_name": "Loilome", "ORCID": "http://orcid.org/0000-0001-8572-5577", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-16T17:24:26Z", "noun_phrases": [ "Sulfasalazine", "metabolic profiles", "cisplatin chemosensitivity", "cholangiocarcinoma cells", "vivo models" ], "doi": "10.1186/s40170-021-00249-6", "access": "open", "takeaways": " Sulfasalazine (SSZ) is widely known as an xCT inhibitor suppressing CD44v9-expressed cancer stem-like cells . Cholangiocarcinoma (CCA) has a high recurrence rate and no effective chemotherapy .", "categories": [] }, { "article_id": 569, "title": "Effects of a positive thinking program on hope and sleep quality in Iranian patients with thalassemia: a randomized clinical trial", "summary": "Background: Thalassemia have a negative impact on the patients' psychological health and sleep quality. This study aimed to determine the effects of a positive thinking training program on hope and sleep quality of patients with thalassemia major.MethodsThis randomized clinical trial was conducted on 78 patients with thalassemia major including 36 males (46.2%) and 42 females (53.8%) with a mean age of 25.56 ± 29.6 in Iran. Subjects were randomly assigned into experimental and control groups. Experimental group received 16 h training based on positive thinking materials published by Martin Seligman. Control group received only usual programs. Data were collected at baseline, as well as immediately and one month after the intervention, using Snyder’s Hope Scale and the Pittsburgh Sleep Quality Index. Data analysis was performed using SPSS Software 18.0; statistical tests included the independent T-test, the Chi-square, Mann Whitney, and Friedman test. Significance level was set at 0.05 in this study.ResultsThe experimental group had a significantly higher mean hope score compared to the control group immediately (45.38 ± 7.82 vs. 35.32 ± 5.54, P < 0.001) and one month following intervention (44.67 ± 3.47 vs. 35 ± .54, P < 0.001). Moreover, the mean sleep quality scores of the experimental group was significantly greater than that for control group immediately (5.35 ± 2.02 vs. 7 ± 2.4, P = 0.004) and one month after the intervention (4.23 ± 2.2 vs.7.02 ± 3.03, P < 0.001).ConclusionSince our training program on positive thinking improved hope and quality of sleep in patients with thalassemia major, we recommend the use of such courses as an important step toward promotion of hope and sleep quality among these patients.Trial registration The name of the registry: Iranian Registry of Clinical Trials. Trial Registration Number: IRCT2017010431774N1. URL of the trial registry record: https://en.irct.ir/trial/24923. Registration Date: 07/03/2017.", "link": "https://bmcpsychology.biomedcentral.com/articles/10.1186/s40359-021-00547-0", "published_date": "2021-03-16T00:00:00Z", "sources": [ "BioMedCentral" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "BMC Psychology", "authors": [ { "author_id": 244602, "given_name": "Somayeh", "family_name": "Makaremnia", "ORCID": null, "country": null }, { "author_id": 244604, "given_name": "Marieh", "family_name": "Dehghan Manshadi", "ORCID": null, "country": null }, { "author_id": 185379, "given_name": "Zahra", "family_name": "Khademian", "ORCID": "http://orcid.org/0000-0001-8366-204X", "country": "IR" } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-16T17:24:26Z", "noun_phrases": [ "Effects", "a positive thinking program", "hope", "quality", "Iranian patients", "thalassemia", "a randomized clinical trial" ], "doi": "10.1186/s40359-021-00547-0", "access": "open", "takeaways": " The study aimed to determine the effects of a positive thinking training program on hope and sleep quality of patients with thalassemia major . The experimental group had a significantly higher mean hope score compared to the control group .", "categories": [] }, { "article_id": 570, "title": "BET bromodomain inhibitors PFI-1 and JQ1 are identified in an epigenetic compound screen to enhance C9ORF72 gene expression and shown to ameliorate C9ORF72-associated pathological and behavioral abnormalities in a C9ALS/FTD model", "summary": "Background: An intronic GGGGCC (G4C2) hexanucleotide repeat expansion (HRE) in the C9ORF72 gene is the most common cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), referred to as C9ALS/FTD. No cure or effective treatment exist for C9ALS/FTD. Three major molecular mechanisms have emerged to explain C9ALS/FTD disease mechanisms: (1) C9ORF72 loss-of-function through haploinsufficiency, (2) dipeptide repeat (DPR) proteins mediated toxicity by the translation of the repeat RNAs, and more controversial, (3) RNA-mediated toxicity by bidirectional transcription of the repeats that form intranuclear RNA foci. Recent studies indicate a double-hit pathogenic mechanism in C9ALS/FTD, where reduced C9ORF72 protein levels lead to impaired clearance of toxic DPRs. Here we explored whether pharmacological compounds can revert these pathological hallmarks in vitro and cognitive impairment in a C9ALS/FTD mouse model (C9BAC). We specifically focused our study on small molecule inhibitors targeting chromatin-regulating proteins (epidrugs) with the goal of increasing C9ORF72 gene expression and reduce toxic DPRs.ResultsWe generated luciferase reporter cell lines containing 10 (control) or ≥ 90 (mutant) G4C2 HRE located between exon 1a and 1b of the human C9ORF72 gene. In a screen of 14 different epidrugs targeting bromodomains, chromodomains and histone-modifying enzymes, we found that several bromodomain and extra-terminal domain (BET) inhibitors (BETi), including PFI-1 and JQ1, increased luciferase reporter activity. Using primary cortical cultures from C9BAC mice, we further found that PFI-1 treatment increased the expression of V1-V3 transcripts of the human mutant C9ORF72 gene, reduced poly(GP)-DPR inclusions but enhanced intranuclear RNA foci. We also tested whether JQ1, an BETi previously shown to reach the mouse brain by intraperitoneal (i.p.) injection, can revert behavioral abnormalities in C9BAC mice. Interestingly, it was found that JQ1 administration (daily i.p. administration for 7 days) rescued hippocampal-dependent cognitive deficits in C9BAC mice.ConclusionsOur findings place BET bromodomain inhibitors as a potential therapy for C9ALS/FTD by ameliorating C9ORF72-associated pathological and behavioral abnormalities. Our finding that PFI-1 increases accumulation of intranuclear RNA foci is in agreement with recent data in flies suggesting that nuclear RNA foci can be neuroprotective by sequestering repeat transcripts that result in toxic DPRs.", "link": "https://clinicalepigeneticsjournal.biomedcentral.com/articles/10.1186/s13148-021-01039-z", "published_date": "2021-03-16T00:00:00Z", "sources": [ "BioMedCentral" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "Clinical Epigenetics", "authors": [ { "author_id": 242395, "given_name": "Esteban", "family_name": "Quezada", "ORCID": null, "country": null }, { "author_id": 242396, "given_name": "Claudio", "family_name": "Cappelli", "ORCID": null, "country": null }, { "author_id": 242398, "given_name": "Iván", "family_name": "Diaz", "ORCID": null, "country": null }, { "author_id": 242399, "given_name": "Nur", "family_name": "Jury", "ORCID": null, "country": null }, { "author_id": 242401, "given_name": "Nicholas", "family_name": "Wightman", "ORCID": null, "country": null }, { "author_id": 189921, "given_name": "Robert H.", "family_name": "Brown", "ORCID": "http://orcid.org/0000-0001-6062-1528", "country": null }, { "author_id": 242402, "given_name": "Martín", "family_name": "Montecino", "ORCID": null, "country": null }, { "author_id": 148179, "given_name": "Brigitte", "family_name": "van Zundert", "ORCID": "http://orcid.org/0000-0002-4129-9972", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-16T17:24:26Z", "noun_phrases": [ "BET", "inhibitors", "JQ1", "an epigenetic compound screen", "C9ORF72 gene expression", "C9ORF72-associated pathological and behavioral abnormalities", "a C9ALS/FTD model" ], "doi": "10.1186/s13148-021-01039-z", "access": "open", "takeaways": " An intronic GGGGCC (G4C2) hexanucleotide repeat expansion (HRE) in the C9ORF72 gene is the most common cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) No cure or effective treatment exist for C9ALS/FTD .", "categories": [] }, { "article_id": 566, "title": "Neurological manifestations as the predictors of severity and mortality in hospitalized individuals with COVID-19: a multicenter prospective clinical study", "summary": "Background: sThe reports of neurological symptoms are increasing in cases with coronavirus disease 2019 (COVID-19). This multi-center prospective study was conducted to determine the incidence of neurological manifestations in hospitalized cases with COVID-19 and assess these symptoms as the predictors of severity and death.MethodsHospitalized males and females with COVID-19 who aged over 18 years were included in the study. They were examined by two neurologists at the time of admission. All survived cases were followed for 8 weeks after discharge and 16 weeks if their symptoms had no improvements.ResultsWe included 873 participants. Of eligible cases, 122 individuals (13.97%) died during hospitalization. The most common non-neurological manifestations were fever (81.1%), cough (76.1%), fatigue (36.1%), and shortness of breath (27.6%). Aging, male gender, co-morbidity, smoking, hemoptysis, chest tightness, and shortness of breath were associated with increased odds of severe cases and/or mortality. There were 561 (64.3%) cases with smell and taste dysfunctions (hyposmia: 58.6%; anosmia: 41.4%; dysguesia: 100%). They were more common among females (69.7%) and non-smokers (66.7%). Hyposmia/anosmia and dysgeusia were found to be associated with reduced odds of severe cases and mortality. Myalgia (24.8%), headaches (12.6%), and dizziness (11.9%) were other common neurological symptoms. Headaches had negative correlation with severity and death due to COVID-19 but myalgia and dizziness were not associated. The cerebrovascular events (n = 10) and status epilepticus (n = 1) were other neurological findings. The partial or full recovery of smell and taste dysfunctions was found in 95.2% after 8 weeks and 97.3% after 16 weeks. The parosmia (30.9%) and phantosmia (9.0%) were also reported during 8 weeks of follow-up. Five cases with mild headaches and 5 cases with myalgia were reported after 16 weeks of discharge. The demyelinating myelitis (n = 1) and Guillain-Barré syndrome (n = 1) were also found during follow-up.ConclusionNeurological symptoms were found to be prevalent among individuals with COVID-19 disease and should not be under-estimated during the current pandemic outbreak.", "link": "https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-021-02152-5", "published_date": "2021-03-16T00:00:00Z", "sources": [ "BioMedCentral" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "BMC Neurology", "authors": [ { "author_id": 230101, "given_name": "Man", "family_name": "Amanat", "ORCID": "http://orcid.org/0000-0002-1197-0833", "country": null }, { "author_id": 162389, "given_name": "Nima", "family_name": "Rezaei", "ORCID": "http://orcid.org/0000-0002-3836-1827", "country": null }, { "author_id": 189564, "given_name": "Mehrdad", "family_name": "Roozbeh", "ORCID": "http://orcid.org/0000-0001-6043-2866", "country": "IR" }, { "author_id": 268204, "given_name": "Maziar", "family_name": "Shojaei", "ORCID": null, "country": null }, { "author_id": 297751, "given_name": "Abbas", "family_name": "Tafakhori", "ORCID": null, "country": null }, { "author_id": 297752, "given_name": "Anahita", "family_name": "Zoghi", "ORCID": null, "country": null }, { "author_id": 268195, "given_name": "Ilad Alavi", "family_name": "Darazam", "ORCID": null, "country": null }, { "author_id": 297753, "given_name": "Mona", "family_name": "Salehi", "ORCID": null, "country": null }, { "author_id": 297754, "given_name": "Ehsan", "family_name": "Karimialavijeh", "ORCID": null, "country": null }, { "author_id": 297755, "given_name": "Behnam Safarpour", "family_name": "Lima", "ORCID": null, "country": null }, { "author_id": 297756, "given_name": "Amir", "family_name": "Garakani", "ORCID": null, "country": null }, { "author_id": 297757, "given_name": "Alexander", "family_name": "Vaccaro", "ORCID": null, "country": null }, { "author_id": 255408, "given_name": "Mahtab", "family_name": "Ramezani", "ORCID": null, "country": null } ], "relevant": false, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-16T15:23:37Z", "noun_phrases": [ "Neurological manifestations", "the predictors", "severity", "mortality", "hospitalized individuals", "COVID-19", "a multicenter prospective clinical study" ], "doi": "10.1186/s12883-021-02152-5", "access": "open", "takeaways": " The reports of neurological symptoms are increasing in cases with coronavirus disease 2019 (COVID-19) The most common non-neurological manifestations were fever (81.1%), cough (76.1%) fatigue (36.6%), and shortness of breath (27.6%) Aging, male gender, co-morbidity, smoking, hemoptysis, chest tightness, and/or mortality were associated with increased odds of severe cases .", "categories": [] }, { "article_id": 567, "title": "Trait mindfulness is primarily associated with depression and not with fatigue in multiple sclerosis (MS): implications for mindfulness-based interventions", "summary": "AbstractObjectivesPersons with MS (PwMS) often display symptoms of depression and fatigue. Mindfulness-based interventions are known to counteract these symptoms. However, to-date the exact relations between trait mindfulness, depression and fatigue remain to be examined. Fatigue is generally regarded as a symptom immanent to the disease and as a direct neurobiological consequence of increased cytokine levels and cortical atrophy. In depression on the other hand, psychosocial factors in the context of adaptation difficulties are probably of higher relevance. Hence, one may argue that mindfulness, as a trait that promotes successful adaption, may show a strong negative association with depression and a relatively minor negative association with fatigue in PwMS.MethodsIn the current study, the association between self-reported trait mindfulness, fatigue and depression was examined in a sample of 69 PwMS.ResultsTrait mindfulness showed highly significant negative correlations with both, depression and fatigue. Mediation analyses however, revealed that depression mediated the relation between mindfulness and fatigue.ConclusionIt may be concluded that in PwMS, trait mindfulness shows a genuine negative association with depression, but that it is only secondarily associated with fatigue. Implications for mindfulness-based interventions in MS are discussed. Based on the results of the current study, it may be feasible to promote the acceptance of default fatigue symptoms, instead of an actual reduction of fatigue symptoms.", "link": "https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-021-02120-z", "published_date": "2021-03-16T00:00:00Z", "sources": [ "BioMedCentral" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "BMC Neurology", "authors": [ { "author_id": 267050, "given_name": "Torsten", "family_name": "Sauder", "ORCID": null, "country": null }, { "author_id": 243244, "given_name": "Philipp M.", "family_name": "Keune", "ORCID": null, "country": null }, { "author_id": 243240, "given_name": "Roy", "family_name": "Müller", "ORCID": null, "country": null }, { "author_id": 267051, "given_name": "Thomas", "family_name": "Schenk", "ORCID": null, "country": null }, { "author_id": 319160, "given_name": "Patrick", "family_name": "Oschmann", "ORCID": "http://orcid.org/0000-0003-1480-0896", "country": null }, { "author_id": 243242, "given_name": "Sascha", "family_name": "Hansen", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-16T15:23:37Z", "noun_phrases": [ "Trait mindfulness", "depression", "fatigue", "multiple sclerosis", "MS", "implications", "mindfulness-based interventions" ], "doi": "10.1186/s12883-021-02120-z", "access": "open", "takeaways": " The association between trait mindfulness, fatigue and depression was examined in a sample of 69 MS patients . Mediation analyses revealed that depression mediated the relation between mindfulness and fatigue . Implications for mindfulness-based interventions in MS are discussed .", "categories": [] }, { "article_id": 564, "title": "Recurrent intracranial hemorrhage in a patient with relapsing multiple sclerosis under interferon-beta therapy", "summary": "<div><p>Neurologia. 2021 Mar 12:S0213-4853(21)00011-6. doi: 10.1016/j.nrl.2021.02.002. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33722454/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210316081323&v=2.14.3\">33722454</a> | DOI:<a href=\"https://doi.org/10.1016/j.nrl.2021.02.002\">10.1016/j.nrl.2021.02.002</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33722454/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-12-19T00:29:38.689000Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Elsevier BV", "container_title": "Neurología", "authors": [ { "author_id": 210371, "given_name": "A.", "family_name": "Sánchez-Soblechero", "ORCID": "http://orcid.org/0000-0002-7098-8494", "country": null }, { "author_id": 210372, "given_name": "J.P.", "family_name": "Cuello", "ORCID": "http://orcid.org/0000-0003-0209-8227", "country": null }, { "author_id": 300644, "given_name": "M.L.", "family_name": "Martínez Ginés", "ORCID": null, "country": null }, { "author_id": 300645, "given_name": "A.", "family_name": "Lozano Ros", "ORCID": null, "country": null }, { "author_id": 300646, "given_name": "F.", "family_name": "Romero Delgado", "ORCID": null, "country": null }, { "author_id": 300647, "given_name": "C.", "family_name": "De Andrés", "ORCID": null, "country": null }, { "author_id": 300648, "given_name": "H.", "family_name": "Goicochea Briceño", "ORCID": null, "country": null }, { "author_id": 163635, "given_name": "José Manuel", "family_name": "García Domínguez", "ORCID": "http://orcid.org/0000-0002-5205-3652", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-16T12:13:25Z", "noun_phrases": [ "Recurrent intracranial hemorrhage", "a patient", "multiple sclerosis", "interferon-beta therapy" ], "doi": "10.1016/j.nrl.2021.02.002", "access": "open", "takeaways": "", "categories": [] } ] }